-+ 0.00%
-+ 0.00%
-+ 0.00%
The drug HLX105, a subsidiary of Fosun Pharmaceuticals (600196.SH), was approved for clinical trials
Share
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its holding subsidiary (collectively known as “Fuhong Hanlin”) received approval from the State Drug Administration to inject HLX105 (that is, the PD-1 antibody fusion protein with the IL-2 variant, “HLX105” for short) for the treatment of advanced/metastatic solid tumors. Fu Hong Hanlin plans to conduct clinical research on this drug in China 1 after conditions are met.

HLX105 is a PD-1 antibody fusion protein independently developed by the Group and is intended for the treatment of advanced/metastatic solid tumors. As of October 2026, the Group's cumulative R&D investment for HLX105 at this stage is approximately RMB 40 million (unaudited). As of the announcement date (i.e. November 16, 2026), no antibody fusion protein products targeting PD-1 and fusing the IL-2 variant have been approved for marketing worldwide.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending